Evidence map›Paper›PMID 40310425›Full record

ArticleDiagnostics (Basel, Switzerland)2025

The Prognostic and Predictive Roles of Ataxia-Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy.

Jamshid Hamdard, Harun Muğlu, Ahmet Bilici, Elif Kuzucular, Özgür Açıkgöz, Ömer Fatih Ölmez, Oktay Olmuşçelik, Özcan Yıldız

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jamshid HamdardMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0002-5823-1704
Harun MuğluMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0001-9584-0827
Ahmet BiliciMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0002-0443-6966
Elif KuzucularMedical Pathology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.
Özgür AçıkgözMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0003-2715-4002
Ömer Fatih ÖlmezMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0001-7934-7039
Oktay OlmuşçelikInternal Medicine Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.ORCID 0000-0002-9815-1848
Özcan YıldızMedical Oncology Department, Faculty of Medicine, Medipol University, İstanbul 34214, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ATM expressionnon-small-cell lung canceroverall survivalpembrolizumabprogression-free survival

Identifiers

PMID40310425
PMCPMC12025422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.